[Clinical effectiveness of pefloxacin (abaktal)in the treatment of inflammatory diseases of the kidneys, urinary tracts and genital organs]. 1993

N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova

Pefloxacin (Abaktal) was used in treatment of 83 patients: 14 patients with acute pyelonephritis, 5 patients with carbuncle of the kidney, 17 patients with postoperative acute pyelonephritis, 3 patients with urosepsis, 7 patients with acute prostatitis, 18 patients with chronic pyelonephritis in the phase of active inflammation, 9 patients with exacerbation of chronic prostatitis, 3 patients with acute cystitis, 2 patients with acute urethritis and 5 patients with epididymo-orchitis. Two dosage forms of pefloxacin were used i.e. tablets of 400 mg and ampoules of 5 ml containing 400 mg of the active substance. The treatment course amounted to 7-14 days. In the patients with inflammatory infectious diseases of the lower urinary tracts (cystitis and urethritis) the treatment course amounted up to 5 days. The results of the treatment with the ampoule solutions were good and satisfactory. With the use of the tablets the results were unsatisfactory in 3 patients (8.1 per cent). Satisfactory bacteriological efficacy of the treatment was stated in 89.5 per cent of the cases. The adverse reactions such as nausea, vomiting, diarrhea and skin eruption were recorded in 5 patients (6 per cent).

UI MeSH Term Description Entries
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009393 Nephritis Inflammation of any part of the KIDNEY. Nephritides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D015366 Pefloxacin A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria. 2589 R.B.,Abactal,Peflacine,Pefloxacin Mesylate,Pefloxacin Mesylate Dihydrate,Pefloxacine,Silver Pefloxacin,Dihydrate, Pefloxacin Mesylate,Mesylate Dihydrate, Pefloxacin,Mesylate, Pefloxacin,Pefloxacin, Silver,R.B., 2589
D052801 Male Urogenital Diseases Pathological processes of the male URINARY TRACT and the reproductive system (GENITALIA, MALE). Male Genitourinary Diseases,Genitourinary Disease, Male,Genitourinary Diseases, Male,Male Genitourinary Disease,Male Urogenital Disease,Urogenital Disease, Male,Urogenital Diseases, Male

Related Publications

N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
November 1991, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
January 1986, Urologiia i nefrologiia,
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
April 1954, Munchener medizinische Wochenschrift (1950),
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
March 1953, Connecticut state medical journal,
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
February 1980, Pediatriia,
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
January 1997, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
January 2011, Vestnik khirurgii imeni I. I. Grekova,
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
August 1956, Munchener medizinische Wochenschrift (1950),
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
March 1967, Meditsinskaia sestra,
N A Lopatkin, and A F Darenkov, and I I Derevianko, and T S Perepanova, and G A Kotliarova, and T A Nosova
August 1953, Munchener medizinische Wochenschrift (1950),
Copied contents to your clipboard!